Mast Therapeutics reports third quarter 2014 financial results
Mast Therapeutics reported the net loss for the third quarter of 2014 was $7.9 million, or $0.06 per share, compared to a net loss of $5.3 million, or $0.05 per share, for the same period in 2013. As of Sept. 30, 2014, the Company had cash, and equivalents totaling $43.1 million. October 31, 2014